Skip to main content
Top
Published in: Urolithiasis 3/2010

01-06-2010 | Symposium Paper

Stone composition and metabolic status

Authors: B. S. Bibilash, Adarsh Vijay, Y. M. Fazil Marickar

Published in: Urolithiasis | Issue 3/2010

Login to get access

Abstract

This paper aims to study the correlation between biochemical risk factors of the stone former and the type of oxalate stone formed, namely calcium oxalate monohydrate (COM) and calcium oxalate dehydrate (COD). A retrospective study of 487 patients who had been attending the urinary stone clinic, Trivandrum during 1998–2007 was conducted. The stones retrieved from them were subjected to chemical analysis and FTIR spectrographic analysis. They were categorized into COM, COD, mixed COM+COD and others. Of 142 pure calcium oxalate stone patients, 87 were predominantly COM stone formers and 55 COD stone formers. Their metabolic status of 24 h urine and serum was assessed. The values of urine calcium, phosphorus, uric acid, magnesium, creatinine, oxalate, citric acid, sodium and potassium, serum values of calcium, phosphorus, uric acid, magnesium and creatinine and calculated values of creatinine clearance, tubular reabsorption of phosphate, calcium magnesium ratio and calcium oxalate ratio were recorded. Comparison was made between the COM stone group and the COD stone group. Patients forming COM stones had significantly higher mean values for urine calcium (P < 0.05), oxalate (P < 0.01) and magnesium (P < 0.05) levels and significantly lower level of urine calcium–oxalate ratio (P < 0.01) and urine calcium–magnesium ratio (P < 0.01) compared to COD stone forming patients. All other values failed to show significant difference. Patients, with higher urine oxalate, formed COM stones. Those with low magnesium (which is an inhibitor) formed more of COD stones. Urine calcium was high in both groups without showing significant variation from the mean. In patients with high calcium–oxalate and calcium–magnesium ratios, there is higher chance of forming a COD stone than COM. Identification of the crystallization pattern of the calcium stone will help in selecting treatment modalities.
Literature
1.
go back to reference Trinchieri A, Castelnuovo C, Lizzano R, Zanetti G (2005) Calcium stone disease: a multiform reality. Urol Res 33(3):194–198CrossRefPubMed Trinchieri A, Castelnuovo C, Lizzano R, Zanetti G (2005) Calcium stone disease: a multiform reality. Urol Res 33(3):194–198CrossRefPubMed
2.
go back to reference Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A, Aron M, Singh TP (2005) Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int J Urol 12(1):12–16CrossRefPubMed Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A, Aron M, Singh TP (2005) Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int J Urol 12(1):12–16CrossRefPubMed
3.
go back to reference Lemann J (1996) Calcium and phosphate metabolism: an overview in health and in calcium stone formers. In: Coe F, Pak CY, Parks JH, Preminger GM (eds) Kidney stones medical and surgical Management. Lipincott-Raven, Philadelphia, p 264 Lemann J (1996) Calcium and phosphate metabolism: an overview in health and in calcium stone formers. In: Coe F, Pak CY, Parks JH, Preminger GM (eds) Kidney stones medical and surgical Management. Lipincott-Raven, Philadelphia, p 264
4.
go back to reference Jeghers H, Murphy R (1945) Practical aspects of oxalalate metabolism. N Engl J Med 292:756 Jeghers H, Murphy R (1945) Practical aspects of oxalalate metabolism. N Engl J Med 292:756
5.
go back to reference Albuquerque PF, Tuma M (1962) Investigations on urolithiasis. II. Studies on oxlalate. J Urol 87:504 Albuquerque PF, Tuma M (1962) Investigations on urolithiasis. II. Studies on oxlalate. J Urol 87:504
6.
go back to reference Milliner DS, Wilson DM, Smith LH (1998) Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J Nephrol 11(Suppl 1):56–59PubMed Milliner DS, Wilson DM, Smith LH (1998) Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J Nephrol 11(Suppl 1):56–59PubMed
7.
go back to reference Rudman D, Kutner MH, Redd SC et al (1982) Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 55:1052–1057CrossRefPubMed Rudman D, Kutner MH, Redd SC et al (1982) Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 55:1052–1057CrossRefPubMed
8.
go back to reference Nicar MJ, Skurla C, Sakhaee K et al (1983) Low urinary citrate excretion in nephrolithiasis. Urology 21:8–14CrossRefPubMed Nicar MJ, Skurla C, Sakhaee K et al (1983) Low urinary citrate excretion in nephrolithiasis. Urology 21:8–14CrossRefPubMed
9.
go back to reference Hosking DH, Wilson JW, Liedtke RR et al (1985) Urinary citrate excretion in normal persons and patients with idiopathic calcium urolithiasis. J Lab Clin Med 106:682–689PubMed Hosking DH, Wilson JW, Liedtke RR et al (1985) Urinary citrate excretion in normal persons and patients with idiopathic calcium urolithiasis. J Lab Clin Med 106:682–689PubMed
10.
go back to reference Kok DJ, Papapoulos SE, Bijvoet OL (1987) Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers. Contrib Nephrol 58:73–77PubMed Kok DJ, Papapoulos SE, Bijvoet OL (1987) Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers. Contrib Nephrol 58:73–77PubMed
11.
go back to reference Cupisti A, Morelli E, Lupetti S et al (1992) Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 61:73–76CrossRefPubMed Cupisti A, Morelli E, Lupetti S et al (1992) Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 61:73–76CrossRefPubMed
12.
go back to reference Kohler P, Uhle C (1966) Oral magnesium intake and its effect on various urinay constituents in the prophylaxis of urolithiasis. J Urol 96:812–815PubMed Kohler P, Uhle C (1966) Oral magnesium intake and its effect on various urinay constituents in the prophylaxis of urolithiasis. J Urol 96:812–815PubMed
13.
go back to reference Melnick I, Landes RR, Hoffman AA et al (1971) Magnesium therapy for recurring calcium oxalate urinary calculi. J Urol 105:119–122PubMed Melnick I, Landes RR, Hoffman AA et al (1971) Magnesium therapy for recurring calcium oxalate urinary calculi. J Urol 105:119–122PubMed
14.
go back to reference Takasaki E (1975) Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis. Invest Urol 12:251–254PubMed Takasaki E (1975) Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis. Invest Urol 12:251–254PubMed
15.
go back to reference Fetner CD, Barilla DE, Townsend J et al (1978) Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis. J Urol 120:399–401PubMed Fetner CD, Barilla DE, Townsend J et al (1978) Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis. J Urol 120:399–401PubMed
16.
go back to reference Johansson G, Backman U, Danielson BG et al (1980) Magnesium metabolism in renal stone disease. Invest Urol 18:93–96PubMed Johansson G, Backman U, Danielson BG et al (1980) Magnesium metabolism in renal stone disease. Invest Urol 18:93–96PubMed
17.
go back to reference Wunderlich W (1981) Aspects of the influence of magnesium ions on the formation of calcium oxalate. Urol Res 9:157–161CrossRefPubMed Wunderlich W (1981) Aspects of the influence of magnesium ions on the formation of calcium oxalate. Urol Res 9:157–161CrossRefPubMed
18.
go back to reference Resnick MI, Munday D, Boyce WH (1982) Magnesium excretion and calcium oxalate urolithiasis. Urology 20:385–389CrossRefPubMed Resnick MI, Munday D, Boyce WH (1982) Magnesium excretion and calcium oxalate urolithiasis. Urology 20:385–389CrossRefPubMed
19.
go back to reference Li MK, Blacklock NJ, Garside J (1985) Effects of magnesium on calcium oxalate crystallization. J Urol 133:123–125PubMed Li MK, Blacklock NJ, Garside J (1985) Effects of magnesium on calcium oxalate crystallization. J Urol 133:123–125PubMed
20.
go back to reference Kohri K, Garside J, Blacklock NJ (1988) The role of magnesium in calcium oxalate urolithiasis. Br J Urol 61:107–115CrossRefPubMed Kohri K, Garside J, Blacklock NJ (1988) The role of magnesium in calcium oxalate urolithiasis. Br J Urol 61:107–115CrossRefPubMed
21.
go back to reference Schwille PO, Schmiedl A, Herrmann U et al (1999) Magnesium, citrate, magnesium citrate and magnesium alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 27:117–126CrossRefPubMed Schwille PO, Schmiedl A, Herrmann U et al (1999) Magnesium, citrate, magnesium citrate and magnesium alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 27:117–126CrossRefPubMed
22.
go back to reference Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed
23.
go back to reference Takasaki E (1972) The magnesium:calcium ratio in the concentrated urines of patients with calcium oxalate calculi. Invest Urol 10:147–150PubMed Takasaki E (1972) The magnesium:calcium ratio in the concentrated urines of patients with calcium oxalate calculi. Invest Urol 10:147–150PubMed
Metadata
Title
Stone composition and metabolic status
Authors
B. S. Bibilash
Adarsh Vijay
Y. M. Fazil Marickar
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Urolithiasis / Issue 3/2010
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-009-0229-x

Other articles of this Issue 3/2010

Urolithiasis 3/2010 Go to the issue